When should low-molecular-weight heparin be monitored?
Fairweather
R B
RB
Clinical Pathology Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip; D001780:Blood Coagulation Tests; D003937:Diagnosis, Differential; D016903:Drug Monitoring / Q000379:methods*; D006470:Hemorrhage / Q000139:chemically induced / Q000175:diagnosis; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010338:Pathology, Clinical / Q000379:methods
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight